Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Different Materials Are Forming the Future of 3D Printing

Hobbyists and artists have utilized a wide variety of materials in their 3D printing experimentation, from ceramics to even sugar and sand.[1] The tight control and consistency that 3D printing offers users has so far encouraged experimentation in numerous sectors. As 3D printing begins to disrupt commercial industries such as construction, a select few materials…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Hobbyists and artists have utilized a wide variety of materials in their 3D printing experimentation, from ceramics to even sugar and sand.[1] The tight control and consistency that 3D printing offers users has so far encouraged experimentation in numerous sectors. As 3D printing begins to disrupt commercial industries such as construction, a select few materials have emerged as reliable, flexible, and cost-effective.

3D printing has numerous uses at nearly every stage of the construction process. Among the earliest adopters of 3D printing tech relied on it for detailed, complex, and entirely three-dimensional prototype models that used most of the same materials the final product would.[2] This “additive manufacturing” (AM) evolved to allow for onsite printing, slashing labor costs and safety concerns.[3] These demonstrations have rapidly driven up the frequency of 3D printing applications in fields like healthcare and aircraft manufacturing as well as construction. So far, metals, plastics, and ceramics have come to dominate these emerging materials markets.

Plastics and polymers are among the most widely used materials for creating small prototypes to printing affordable housing in developing countries. Acrylonitrile Butadiene Styrene (ABS), Polylactic Acid (PLA), and the polyamides PA11/PA12 are the foremost polymers being pushed by European firms such as France’s Arkema SA and Germany’s Evonik AG.[4] A specialized form of concrete that requires a supersize printer will set as it’s being printed and, due to its composite nature, is much more supportive than conventional materials.[5]

An important aspect of this burgeoning market is less the type of material itself and more the form it takes. Powder-based AM calls for powder forms of metals like titanium as well as plastics like ABS and PLA. New patents for the creation of these powders are pending while manufacturers expand their capacity to keep up with growing global demand.[6] New materials like thermoplastic filaments, resins that are photosensitive, and more are in development now, with a whole new set of applications likely to emerge.

Though the 3D printing artists of the world may not be the ones to build new homes, their experimental instincts have no doubt influenced manufacturers to follow suit. 3D printing remains a nascent technology with significant room for growth.

For the latest news, videos, and podcasts in the AEC Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

[1] https://architizer.com/blog/inspiration/industry/data-clay/

[2] https://3dprintingindustry.com/news/top-10-3d-printed-construction-innovations-83578/

[3] https://www.researchgate.net/publication/303749537_Processing_and_properties_of_construction_materials_for_3D_printing

[4] https://blog.marketresearch.com/5-key-trends-in-3d-printing-materials

[5] https://www.forbes.com/sites/sap/2018/08/20/how-3d-printing-is-disrupting-the-materials-building-industry/#d1b131c1fdc7

[6] https://www.idtechex.com/research/reports/3d-printing-materials-2018-2028-technology-and-market-analysis-000583.asp

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512